Clinical Research Of Vinorelbine Plus Apatinib In Treatment Of Non-Small Cell Lung Cancer

Background and purposeLung cancer is one of the most common malignant tumors in the world today,and has become a major disease that seriously threatens the health of human beings.According to WHO statistics,in China,there were 4.28 million cancer patients in 2018,and more than 2.86 million deaths.Whether in the world or in China,the incidence and mortality of lung cancer are the highest among all types of malignant tumors,and the population of the disease has a tendency to develop towards a younger population.Among them,non-small cell lung cancer accounts for 80%of the total number of lung cancer patients,is the most common and most malignant lung cancer?The treatment of advanced non-small cell lung cancer has made great progress in recent years.The third-generation chemotherapy drugs such as vinorelbine,gemcitabine,paclitaxel and docetaxel combined with platinum two-drug chemotherapy are still the routine of first-line treatment of NSCLC.One of the new treatments since 2003 is molecular targeting of epidermal growth factor tyrosine kinase inhibitors(EGFR TKI)and vascular endothelial growth factor(VEGF)inhibitors for the treatment of advanced non-small cell lung cancer.Gefitinib and erlotinib and octatinib are commonly used targeted drugs for lung cancer,but they are limited to patients with positive mutations and cannot be widely used clinically.The role of anti-tumor angiogenesis therapy in the treatment of tumors is extremely important,and most treatments are through the pathways acting on vascular endothelial growth factor(VEGF)and its receptor(VEGFR).A large number of preclinical studies and clinical trials have shown that apatinib has a wide range of anti-tumor effects on a variety of solid tumors including gastric cancer,non-small cell lung cancer,breast cancer and liver cancer.This article aims to investigate the clinical efficacy,toxicity and safety of vinorelbine plus apatinib in the treatment of non-small cell lung cancer.Method A total of 94 Non-small cell lung cancer patients were randomly divided into control group and experience group.Each group included 47 patients.The experience group was treated by Vinorelbine plus Apatinib,while the control group treated by Vinorelbine plus Cisplatin.The recent efficacy,long-term efficacy(PFS and OS),KPS score and adverse reactions between the two groups were observed.Results The recent efficacy of the experience group was 74.5%,which was significantly higher than the control group(P<0.05).The median PFS of the study group was 7.13 months and median OS was 12.90 months,which were significantly higher than the control group(P<0.05).The KPS score response rate of the experience group were 72.3%,which were significantly higher than the control group(P<0.05).The adverse reactions of the two groups included bone marrow depression,gastrointestinal reactions,dysfunction of liver,blood pressure increase,hand-foot syndrome,weakness and proteinuria.The incidence adverse reactions between the two groups were no significant difference(P>0.05).Conclusions Vinorelbine plus Apatinib treating the non-small cell lung cancer can significantly improve the recent efficacy,prolong survival period and the adverse reactions are easy to control.It is worthy of promotion.